Skip to main content
Top
Published in:

09-05-2024 | Cytostatic Therapy | ASO Author Reflections

ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?

Authors: Daisaku Yamada, MD, PhD, Shogo Kobayashi, MD, PhD, Hidenori Takahashi, MD, PhD, Yoshifumi Iwagami, MD, PhD, Hirofumi Akita, MD, PhD, Kei Asukai, MD, PhD, Junzo Shimizu, MD, PhD, Terumasa Yamada, MD, PhD, Masahiro Tanemura, MD, PhD, Shigekazu Yokoyama, MD, PhD, Masanori Tsujie, MD, PhD, Tadafumi Asaoka, MD, PhD, Yutaka Takeda, MD, PhD, Osakuni Morimoto, MD, PhD, Akira Tomokuni, MD, PhD, Yuichiro Doki, MD, PhD, Hidetoshi Eguchi, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2024

Login to get access

Excerpt

The optimal neoadjuvant chemotherapy (NAC) regimen for patients with R/BR-PDAC remains uncertain.15 We conducted the first trial comparing the efficacy and safety of two candidate regimens: GEM+nPTX (GA) and GEM+S-1 (GS). …
Literature
1.
go back to reference Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91–100.CrossRefPubMed Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91–100.CrossRefPubMed
2.
go back to reference Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.CrossRefPubMedPubMedCentral Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.CrossRefPubMedPubMedCentral
3.
go back to reference Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol 2019;37(15suppl):4126. Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol 2019;37(15suppl):4126.
4.
go back to reference Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(15suppl):4504.CrossRef Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(15suppl):4504.CrossRef
5.
go back to reference Daisaku Y, Shogo K, Hidenori T, et al. Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015). Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15199-8.CrossRef Daisaku Y, Shogo K, Hidenori T, et al. Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015). Ann Surg Oncol. 2024. https://​doi.​org/​10.​1245/​s10434-024-15199-8.CrossRef
Metadata
Title
ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
Authors
Daisaku Yamada, MD, PhD
Shogo Kobayashi, MD, PhD
Hidenori Takahashi, MD, PhD
Yoshifumi Iwagami, MD, PhD
Hirofumi Akita, MD, PhD
Kei Asukai, MD, PhD
Junzo Shimizu, MD, PhD
Terumasa Yamada, MD, PhD
Masahiro Tanemura, MD, PhD
Shigekazu Yokoyama, MD, PhD
Masanori Tsujie, MD, PhD
Tadafumi Asaoka, MD, PhD
Yutaka Takeda, MD, PhD
Osakuni Morimoto, MD, PhD
Akira Tomokuni, MD, PhD
Yuichiro Doki, MD, PhD
Hidetoshi Eguchi, MD, PhD
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15244-6

Other articles of this Issue 7/2024

Annals of Surgical Oncology 7/2024 Go to the issue
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare